Evaluation of efficacy of Cranberry in management of non-alcoholic fatty liver patients

Abstract

In the present clinical trial, we aimed to evaluate the effect of cranberry supplementation on serum liver enzymes, hepatic steatosis, and glycemic and lipid profiles in patients with non-alcoholic fatty liver (NAFLD). Materials and methods: In this two-arm, parallel design, double-blind randomized controlled clinical trial, 110 volunteer patients with NAFLD were enrolled. The patients were randomized to receive 144 mg cranberry capsule or placebo for 6 months. The primary efficacy of the treatment was lipid profile, glycemic measurements, and liver enzyme levels. Results: The data were reported for 94 patients (46 in the supplementation group and 48 in the placebo group). The mean (SD) age of the participants was 43.16 (11.08) years. There were no significant differences between groups regarding the after-intervention level of liver enzyme. The mean after-intervention levels of total cholesterol (p<0.001) and triglyceride (p=0.01) were significantly lower in the intervention group compared with the placebo group. At the end of the study, the mean insulin and HOMA-IR levels were significantly lower in the cranberry group compared with the placebo group. Significantly more patients in the cranberry group experienced a decrease in steatosis level compared with the control group.